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Abstract In recent years, human immunodeficiency virus
(HIV)-infected patients under highly active anti-retroviral
therapy (HAART) regimens have shown a markedly im-
proved general clinical status; however, the prevalence of
mild cognitive disorders has increased. We propose that
increased longevity with HIV-mediated chronic inflammation
combined with the secondary effects of HAART may
increase the risk of early brain aging as shown by intra-
neuronal accumulation of abnormal protein aggregates like
amyloid β (Aβ), which might participate in worsening the
neurodegenerative process and cognitive impairment in older
patients with HIV. For this purpose, levels and distribution of
Aβ immunoreactivity were analyzed in the frontal cortex of
43 patients with HIV (ages 38–60) and HIV− age-matched
controls. Subcellular localization of the Aβ-immunoreactive
material was analyzed by double labeling and confocal
microscopy and by immunono-electron microscopy (EM).
Compared to HIV− cases, in HIV+ cases, there was abundant
intracellular Aβ immunostaining in pyramidal neurons and
along axonal tracts. Cases with HIVencephalitis (HIVE) had
higher levels of intraneuronal Aβ immunoreactivity com-
pared to HIV+ cases with no HIVE. Moreover, levels of
intracellular Aβ correlated with age in the group with
HIVE. Double-labeling analysis showed that the Aβ-
immunoreactive granules in the neurons co-localized with
lysosomal markers such as cathepsin-D and LC3. Ultrastruc-
tural analysis by immuno-EM has confirmed that in these
cases, intracellular Aβ was often found in structures display-
ing morphology similar to autophagosomes. These findings
suggest that long-term survival with HIVmight interfere with
clearance of proteins such as Aβ and worsen neuronal
damage and cognitive impairment in this population.
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Introduction
In the age of highly active antiretroviral therapy (HAART),
the survival of patients with AIDS has increased, and the
proportion of HIV patients over the age of 50 has become
significant. A recent study (Valcour et al. 2004a) found that
individuals over 50 years of age represent 11% of the HIV
cases registered by the Centers for Disease Control and
Prevention (CDC). Data from the Hawaii cohort suggest an
association between increased neurocognitive impairment
in older HIV patients compared with younger controls
(Valcour et al. 2004a, b, c, 2005; Valcour and Shiramizu
2004). Moreover, in a study in Western Pennsylvania (Becker
et al. 2004), the prevalence of cognitive disorder among
HIV-positive patients over 50 years of age was significantly
higher than in younger individuals. Factors leading to this
association may include vascular pathology, age-related
immunological changes, and limited compensatory brain
capacity. This suggests that chronic HIV infection and
aging have similar effects on global cognitive functioning.
Progressive brain dysfunction associated with aging has been
linked to synapto-dendritic damage, reduced neurotransmitter
production, and increased neuro-inflammatory reactivity
associated with formation of radical oxygen species (Agrawal
et al. 2006; Platenik et al. 2001; Price et al. 2006; Reynolds
et al. 2007; Visalli et al. 2007).
Also contributing to the neuronal injury in older HIV
patients might be the chronic permanence of HIV in the
CNS. The HIV reservoir in the brain is known to be more
difficult to reach because of the limited penetrance of
HAART, emergence of resistant species, and viral escape
(Dunfee et al. 2006; Langford et al. 2004).
Thus, despite the beneficial effects of HAART at sup-
pressing viral load peripherally, the continued prevalence of
moderate neurocognitive alterations in patients with HIV
(Ances et al. 2008; Tozzi et al. 2007) might be related to the
persistence of HIV in the CNS. Therefore, HIV encephalitis
(HIVE) has shifted from a subacute neuro-inflammatory
condition with abundant multinucleated giant cells to a
more chronic and protracted condition with moderate
astrogliosis, microgliosis, and viral load but more extensive
neurodegeneration.
HAART has modified the patterns of HIV-related neuro-
pathology and clinical manifestations in the past 10 years
with the emergence of new variants of HIV encephalopathy
(Everall et al. 2006). A paramount co-pathogenic factor in
the long-term survival of patients with HIV on HAART
is age. During aging, there is a failure in the handling
and clearance of misfolded proteins such as Aβ and α-
synuclein. Misfolded proteins can be cleared via lysosomal
(e.g., autophagy) and non-lysosomal pathways (e.g., pro-
teasome; Williams et al. 2006). In Alzheimer’s disease
(AD) and other neurodegenerative disorders, this is
manifested by increased accumulation of Aβ into toxic
oligomers (Barghorn et al. 2005; Deshpande et al. 2006;
Glabe 2008; Shin et al. 2008; Standridge 2006; Tsigelny et
al. 2008; Watson et al. 2005; White et al. 2005; Wisniewski
and Konietzko 2008; Yoshiike et al. 2003; Selkoe 2008).
Recent studies have suggested that in addition to the extra-
cellular deposition of Aβ, in AD, a smaller but significant
fraction might accumulate intraneuronally (Arvanitis et al.
2007; Cuello 2005; Cuello and Canneva 2008; Echeverria
and Cuello 2002; Grant et al. 2000; Green et al. 2005).
Previous studies have shown that in aged HIV patients,
there is increased amyloid deposition and plaque formation
(Daily et al. 2006; Green et al. 2005; Rempel and Pulliam
2005). However, it was unclear what is the earliest site for
Aβ accumulation in patients with HIV and how this might
be related to the alterations in protein handling during
aging. For this purpose, patterns of intracellular Aβ
accumulation and its relationship with lysosomal clearance
were analyzed in HIV cases ranging in age from 38–60 years
old. Our results indicate that in this population, there is
increased intraneuronal Aβ accumulation in lysosomal–
autophagic structures. These findings suggest that longer-
term survival with HIV might interfere with clearance of
proteins such as Aβ that might worsen neuronal damage and
cognitive impairment in this population.
Materials and methods
Subjects and neuropathological assessment For the present
study, we included a total of 43 HIV+ cases from the HIV
Neurobehavioral Research Center and California Neuro-
AIDS Tissue Network at the University of California San
Diego. Cases had neuromedical and neuropsychological
examinations within a median of 12 months before death.
Most cases died as a result of acute bronchopneumonia or
septicemia, and autopsy was performed within 24 h of
death. Autopsy findings were consistent with AIDS, and
the associated pathology was most frequently due to
systemic CMV, Kaposi sarcoma, and liver disease. Subjects
were excluded if they had a history of CNS opportunistic
infections or non-HIV-related developmental, neurologic,
psychiatric, or metabolic conditions that might affect CNS
functioning (e.g., loss of consciousness exceeding 30 min,
psychosis, substance dependence). In all cases, neuropath-
ological assessment was performed in paraffin sections
from the frontal, parietal, temporal cortices, hippocampus,
basal ganglia, and brainstem stained with H&E or immu-
nolabeled with antibodies against p24 and GFAP (Achim
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et al. 1993; Masliah et al. 1992). The diagnosis of HIVE
was bases on the presence of microglial nodules, astrogliosis,
HIV p24-positive cells, and myelin pallor. Additional
analysis was performed with a subset of five age-matched
(non-HIV) cases from the UCSD—Medical center Autopsy
Service.
Immunocytochemical analysis and image analysis To fur-
ther evaluate the patterns of Aβ immunoreactivity in the
brains of patients with HIV, briefly as previously described
(Rockenstein et al. 2005) vibratome sections from the mid-
frontal cortex (40 μm thick) were incubated overnight at
4°C with the mouse monoclonal antibody against Aβ (clone
4G8; 1:600, Senetek, Napa, CA, USA) or with the antibody
against the N terminus of Aβ (aa 1–16; clone 82E1; Immuno-
Biological Laboratories, Gunma, Japan) followed by incuba-
tion with secondary biotinylated anti-mouse IgG, followed by
ABC and DAB. Sections were transferred to SuperFrost
slides (Fisher Scientific, Tustin, CA, USA) and mounted
under glass coverslips with anti-fading media (Vector
Laboratories, Burlingame, CA, USA). All sections were
processed under the same standardized conditions. From each
case, an average of 50 neurons were imaged, and digital files
were analyzed with the Image Quant system. Three immu-
nolabeled sections were analyzed per case, and the average of
individual measurements was used to calculate group means.
Additional confirmation of the intracellular amyloid labeling
was performed utilizing the Thioflavine-S staining in the
vibratome sections (Rockenstein et al. 2001).
Double immunolabeling and confocal laser microscopy To
evaluate the co-localization between Aβ immunoreactivity
and lysosomal markers, double immunocytochemical
analysis was performed (Belinson et al. 2008). For this
purpose, vibratome sections were immunolabeled with a
monoclonal antibody against Aβ (clone 4G8; 1:600,
Senetek, Napa, CA, USA) detected with FITC-conjugated
secondary antibodies (1:75, Vector Laboratories) and the
antibodies against cathepsin-D, Lamp2, and Rab5 (1:500,
Dako, Carpinteria, CA, USA) detected with the Tyramide
Signal Amplification™-Direct (Red) system (1:100, NEN
Life Sciences, Boston, MA, USA; Pickford et al. 2008). All
sections were processed simultaneously under the same
conditions, and experiments were performed twice to assess
reproducibility. Sections were imaged with a Zeiss 63X
(N.A. 1.4) objective on an Axiovert 35 microscope (Zeiss,
Germany) with an attached MRC1024 LSCM system
(BioRad). To confirm the specificity of primary antibodies,
control experiments were performed where sections were
incubated overnight in the absence of primary antibody
(deleted) or preimmune serum and primary antibody alone.
Immunoelectron microscopy analysis Briefly, vibratome
sections immunostained as described above with the 4G8
antibody or a nonimmune IgG were fixed in 0.25% glutaral-
dehyde and 3% paraformaldehyde in 0.1 M cacodylate
buffer (pH 7.4) and then pre-embedded with 50% Durcupan
epoxy resin, and 50% ethanol (dry) for 30 min. Samples
were then embedded in Durcupan mix epoxy resin and
polymerized under a vacuum at 60°C for 48 h. After the resin
was polymerized, tissues were mounted into plastic cylin-
ders, sectioned with an ultra microtome (Reichert Ultracut E)
at 60 nm thickness and collected in copper grids for
ultrastructural analysis. The immunostained grids were
post-stained using saturated uranyl acetate solution in 50%
ethanol for 20 min at room temperature, washed in distilled
water, and placed in bismuth nitrate solution for 10 min
followed by a final wash in deionized water. The immuno-
labeled grids were analyzed with a Zeiss EM10 electron
microscope and electron micrographs obtained at a magni-
fication of 35,000.
Statistical analysis All the analyses were conducted on
blind-coded samples. After the results were obtained, the
code was broken, and data were analyzed with the StatView
program (SAS Institute, Cary, NC, USA). Comparisons
among groups were performed with unpaired Student’s
T test, Chi square analysis and simple linear regression
analysis. All results were expressed as mean±SEM.
Results
Intraneuronal accumulation of Aβ in HIV patients A total
of 48 cases were included, of which 43 were HIV sero-
positive, and five were HIV seronegative (Table 1). The age

















HIV+, no HIVE 18 15/3 12/5/1 49±1.5 38–60 18±2 7/18 (38%) 1/18 (5%)
HIV+ Yes HIVE 25 21/4 16/9/0 47±1 39–57 19±2 18/25 (72%) 2/25 (8%)
HIV- 5 4/1 0/1/4 47±2 38–55 15±2 0/0 0/0
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range varied between 38 and 60 years with a mean of 48±
2 years. Of the 43 HIV cases, 18 had no significant
opportunistic infections or HIVE, and the other 25 had
HIVE. Immunocytochemical analysis with the antibody
against Aβ (4G8 clone) showed that compared to HIV−
controls (Fig. 1A–C), in seven out of 18 HIV+ cases (38%)
with no HIVE, there was intraneuronal immunolabeling
(Fig. 1D). In contrast, in cases with HIVE, intraneuronal
Aβ immunoreactivity was observed in 18 out of the 25
cases (72%; Fig. 1G). This difference was significant by
Chi square analysis (X2=4.7, p=0.029). The Aβ immuno-
staining was observed in pyramidal neurons in layers 2–3
and 5, had a granular cytoplasmic appearance that was
concentrated in the neuronal cell body (Figs. 1D, G; 2B–E),
although in some cases, extended to the axons (Fig. 1E, H)
and dendrites (Fig. 2D). In the five control cases, there was
very low or no detectable intracellular Aβ immunostaining
(Figs. 1A–C, 2E). Image analysis of the levels of intra-
cellular Aβ immunostaining in the individual cases showed
significantly higher levels in the HIVE compared to HIV+
cases without HIVE (t test, p=0.005; Fig. 2). In one of the
HIV+ cases with no apparent HIVE (Fig. 1F) and in two of
the cases with HIVE, there was evidence of extracellular
Aβ deposition (Fig. 1I). The plaques had a diffuse
appearance and in some cases surrounded neuronal cell
bodies or were observed along axonal tracts (Fig. 3A–C).
Although these diffuse plaques were similar to those
observed in AD, no abundant neuritic plaques or tangles
were detected, thus ruling out the possibility of AD in these
cases. Similar results were observed with the antibody
against the N terminus of Aβ (82E1 clone) and with
thioflavine-S (Fig. 3D–F). Linear regression analysis
showed that there was a significant correlation between
the levels of intracellular Aβ immunoreactivity and age in
the HIV+ group with HIVE (Fig. 4A), but no correlation
was observed in the HIV+ group with no HIVE (Fig. 4 B).
Co-localization of lysosomal markers with the intraneuronal
Aβ in the brains of HIV patients Given the punctate cyto-
plasmic characteristics of the intraneuronal Aβ immuno-
reactivity in the HIV cases and that previous studies have
suggested in experimental models that this might be localized
Fig. 2 Levels of intraneuronal Aβ immunoreactivity in older HIV+
cases. Images are from the frontal cortex immunostained with the
monoclonal antibody 4G8. a–d Examples of the various levels (0–4) of
intraneuronal Aβ immunoreactivity in HIV+ cases; the arrow indicates
the enlarged image to the left displaying punctate appearance. e
Compared to HIV+ with no HIVE, in cases with HIVE, there was an
increase in the levels of intraneuronal Aβ immunoreactivity. Bar=5 μm
Fig. 1 Patterns of Aβ immunoreactivity in control and HIV+ cases.
Panels are from the frontal cortex immunostained with the monoclonal
antibody 4G8. a–c In an age-matched control HIV− case (42 year old)
the neuronal cell bodies (a), axons in the white matter (b), and
neuropil (c) are devoid of amyloid deposits. d–f Examples of
intraneuronal (d) granular Aβ immunoreactivity in an older HIV+
case (47 year old). Aβ deposits can be found in axons (e) and in the
neuropil (f) as diffuse plaques. g–i Examples of intraneuronal (g) and
axonal (h) Aβ immunoreactivity (arrows) in an older HIV+ case
(50 year old) with HIVE. The inset shows in greater detail the
punctate appearance of the intraneuronal Aβ immunostaining. Diffuse
amyloid plaques (i) were also detected in a few cases. Bar=10 μm
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in lysosomal structures, double labeling studies were per-
formed. By confocal microscopy, the Aβ-immunoreactive
structures co-localized with the lysosomal markers cathepsin-
D (Fig. 5D–F) and LAMP2 (Fig. 5 G–I). Moreover, the
Aβ-immunolabeled granular bodies co-localized with the
autophagy marker LC3 (Fig. 5J–L). Overall, these granular
structures were enlarged and clustered; in contrast, in control
cases, discrete cathepsin-D lysosomal structures were iden-
tified that showed no Aβ immunoreactivity (Fig. 5A–C).
To further investigate the intracellular localization of
Aβ, immunolabeled vibratome sections were analyzed by
electron microscopy. Compared to control cases (Fig. 6A),
in the HIV cases with intraneuronal Aβ immunoreactivity,
aggregates were observed associated with structures remi-
niscent of lysosomes and autophagolysosomes in the cell
body and in axonal structures (Fig. 6B, C).
Discussion
The present study showed that in HIV patients, there is a
prominent intraneuronal accumulation of Aβ associated
with lysosomal structures. The intraneuronal Aβ was more
abundant in patients with HIVE compared to HIV cases
with no significant pathology, and in the group with HIVE,
the levels of intracellular Aβ increased with age. These
findings suggest that long-term survival with HIV might
interfere with clearance of proteins such as Aβ that might
worsen neuronal damage and cognitive impairment in this
population. Previous studies have shown in older HIV+
patients the presence of extracellular amyloid deposits
similar to those detected in patients with AD (Green et al.
2005; Rempel and Pulliam 2005).
The first study to identify changes similar to mild AD was
reported by Esiri et al. (1998) who found Aβ plaques in
HIV patients by using argyrophilic and thioflavine stainings.
Another study using a more comprehensive methodology
that included staining with the 4G8 antibody, Congo red, and
Thioflavine-S (Izycka-Swieszewska et al. 2000) showed that
in 15 AIDS cases (five with HIVE), three had perivascular
plaques positive for 4G8 but not Congo Red or Thioflavine-
S. Based on these findings, the authors concluded that the
neurodegeneration associated with HIV infection could be
primarily of vascular origin. Our results suggest that while
Fig. 3 Laser confocal micros-
copy imaging of the amyloid
deposits in HIV+ cases.
Examples are from the frontal
cortex. a No evidence of
amyloid deposits in HIV− age-
matched control; b, c double-
labeling with antibodies against
the neuronal markers NeuN
(red) and Aβ (green) showing
neuronal amyloid deposits
(b, arrows) and diffuse plaques
(c, amyl) in HIV+ cases.
d–f Comparative images in
HIV− (d) and HIV+ (e, f) cases
stained with thioflavine S.
Bar=10 μm
Fig. 4 Linear regression
analysis between intracellular
Aβ and age. a In cases with
HIVE, there was a significant
correlation. b In cases with no
HIVE, there was no significant
correlation
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Fig. 6 Ultrastructural analysis of the Aβ deposits in HIV+ cases.
Sections from the frontal cortex were immunostained pre-embeddingwith
4G8 and analyzed with the electron microscope. a In a control, HIV−
case, evidence of preservation of neuronal organelles such as lysosomes
(lys) and mitochondria (m). b In an HIV+ case, abnormal electrodense
membrane-bounded organelles (arrows) displaying Aβ immuno-
reactivity accumulate in the neuronal cell body and axons. c Additional
view of abnormal electrodense membrane-bounded organelles display-
ing intraneuronal Aβ immunoreactivity in an HIV+ case. Bar=2 μm
Fig. 5 Laser confocal
microscopy imaging of the
intraneuronal Aβ and lysosomal
markers in older HIV+ cases.
Sections are from the frontal
cortex double labeled with the
Aβ (4G8) antibody (green) and
lysosomal proteins cathepsin-D,
LAMP2, and LC3 (red).
a–c HIV− control case. d–l
Co-localization (arrows) of
intraneuronal Aβ and cathepsin-
D (d–f), LAMP2 (g–i), or LC3
(j–l) in an HIV+ case.
Bar=5 μm
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the vascular hypothesis may explain some of the plaques
seen in the AIDS brains, given the intraneuronal accumula-
tion and the neuronal origin of Aβ, this supports a possible
cerebral source of the parenchymal amyloid.
Aβ is the result of the proteolytic processing of APP by
β- and γ-secretases (Findeis 2007; Ghosh et al. 2005; Hoe
and Rebeck 2008; Postina 2008; Russo et al. 2005;
Thinakaran and Koo 2008; Vetrivel and Thinakaran 2006;
Walsh et al. 2007; Wolfe 2006, 2008a, b). APP is
ubiquitously distributed; in the CNS, APP is most abun-
dantly produced by neurons and astroglial cells (Schmechel
et al. 1988). Interestingly, the initial studies in the CNS of
patients with HIV have focused on the levels of APP as a
marker of neuronal injury. Several reports have described a
significant increase in brain APP in AIDS cases, specifi-
cally in the axons of the subcortical white matter tracts. One
leading theory is based on the inflammatory response in
HIV infection of the brain parenchyma, where activated
microglia are considered by many to be the likely source of
mediators of disease that can promote overproduction and
accumulation of APP (Adle-Biassette et al. 1999; Dickson
et al. 1993). Among the brain macrophage-secreted factors
mediating the overproduction of neuronal APP, a leading
candidate is IL-1 (Stanley et al. 1994).
The association between the brain pathology charac-
teristic of HIVE, including viral proteins and the presence
of APP aggregates, often as intra-axonal globules, was
reported in several studies (Giometto et al. 1997; Nebuloni
et al. 2001; Raja et al. 1997). These results were further
confirmed in the simian immunodeficiency virus (SIV)
model of HIVE where Mankowski et al. have also found
APP accumulation in degenerating axons (Mankowski et al.
2002). While the majority of these studies show a strong
correlation between the topography of HIV-associated
pathology and degenerating axons, suggesting a more local,
intraparenchymal effect on APP accumulation, some inves-
tigators disagree. In one of the first studies of APP in the
HIV brain, Scaravilli and colleagues (An et al. 1997) did
not find a good correlation between APP and microgliosis
and concluded that the axonal degeneration in HIV
infection, may be due to systemic factors (e.g. cytokines).
The mechanisms through which HIV infection in the
CNS might lead to increased accumulation of Aβ are not
completely clear. Recent studies suggest that HAART
resistance, chronic HIV infection, HAART toxicity and
reduced clearance of misfolded proteins might play a role
(Hult et al. 2008). Aβ is degraded by proteases such as
neprilysin, insulin-degrading enzyme, and endothelin
(Eckman and Eckman 2005; Miners et al. 2008; Nalivaeva
et al. 2008; Wang et al. 2006). The HIV Tat protein has
been shown to interfere with neprilysin activity, and
HAART has been shown to alter the metabolic routes for
Aβ and insulin processing (Daily et al. 2006; Nath and
Hersh 2005; Rempel and Pulliam 2005). Neprilysin is not
only capable of degrading extracellular but also intra-
cellular Aβ (Spencer et al. 2008). While the clinical benefit
in reducing viral burden is indisputable, HAART is also
reported to induce metabolic dysregulation resulting in a
syndrome of lipodystrophy (LD) in up to 83% of treated
individuals (Carr et al. 1999). Features associated with LD
include insulin resistance with hyperinsulinemia, centripetal
lipohypertrophy with concurrent subcutaneous peripheral
lipoatrophy, and hypertriglyceridemia. The metabolic com-
plications underlying LD include insulin resistance.
Another important mechanism involved in the clearance
of Aβ is the authophagy pathway (Jellinger 2006; Jellinger
and Stadelmann 2001; Li et al. 2007; Lunemann et al.
2007; Nixon 2007; Shacka et al. 2008; Wilson et al. 2004;
Yu et al. 2004, 2005; Zheng et al. 2006). This lysosomal
pathway has been shown to be defective in patients with
HIV (Delhaye et al. 2007; Fredericksen et al. 2002; Levine
and Sodora 2006; Talloczy et al. 2008), and recent studies
in AD patients have shown that alterations in autophagy
leads to increased intracellular and extracellular Aβ
(Pickford et al. 2008). Consistent with this possibility, in
the present study, we showed the intracellular Aβ co-localized
with lysosomal markers and accumulated in structures
reminiscent of lysosomes and abnormal autophagosomes.
In summary, in HIV patients, there is extensive intra-
neuronal accumulation of Aβ suggesting that long-term
survival with HIV might interfere with clearance of proteins
such as Aβ that might worsen neuronal damage and
cognitive impairment in this population.
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